Open AccessSpore powder of Ganoderma lucidum for Alzheimer's disease
Author(s) -
Lianjie Qin,
Chen Wang,
Lianjie Qin,
YanFeng Liang,
Guohui Wang
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000014382
Subject(s) - medicine , medline , data extraction , randomized controlled trial , systematic review , adverse effect , alternative medicine , disease , meta analysis , family medicine , intensive care medicine , pathology , political science , law
Background: Previous studies have reported that spore powder of Ganoderma lucidum (SPGL) may be effective for the treatment of Alzheimer's disease (AD). However, its efficacy is still inconclusive. Thus, this systematic review will aim to assess its efficacy and safety for AD. Methods: We will search the electronic databases of Cochrane Central Register of Controlled Trials, EMBASE, MEDILINE, the Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database to assess the efficacy and safety of SPGL for patients with AD from their inceptions to the present. All case–control studies and randomized controlled trials will be considered for inclusion in this study. Two review authors will independently perform the study selection, data extraction, and risk of bias evaluation. Results: The primary outcome includes the cognitive status for patients. The secondary outcomes consist of the quality of life, AD symptoms, and adverse events. Conclusions: This systematic review will present the existing evidence for the efficacy and safety of SPGL for treating patients with AD. Dissemination and ethics: The results of this systematic review will be disseminated by through peer-reviewed journals. It does not needs ethic approval, because it does not involve individual patient data. Systematic review registration: PROSPERO CRD42019119426.